Characterization of the immune response induced by pertussis OMVs-based vaccine |
| |
| Institution: | 1. Laboratorio VacSal, Instituto de Biotecnología y Biología Molecular (IBBM), Facultad de Ciencias Exactas, Universidad Nacional de La Plata, CCT-CONICET La Plata, Calles 50 y 115, 1900 La Plata, Argentina;2. Instituto de Estudios Inmunológicos y Fisiopatológicos (IIFP), Facultad de Ciencias Exactas, Universidad Nacional de La Plata, CCT-CONICET La Plata, 47 y 115, 1900 La Plata, Argentina;1. Novartis Vaccines and Diagonstics SrL (a GSK Company), Via Fiorentina 1, 53100 Siena, Italy;2. Università degli Studi di Padova, 35129 Padova, Italy;3. Università di Siena, 53100 Siena, Italy;4. GlaxoSmithKline (former Novartis Vaccines), 350 Massachusetts Ave, Cambridge, 02139 MA, USA;1. Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY 14853, USA;2. Department of Biological and Environmental Engineering, Cornell University, Ithaca, NY 14853, USA;3. School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY 14853, USA;4. Department of Microbiology and Immunology, Cornell University, Ithaca, NY 14853, USA;1. Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Australia;2. Murdoch Childrens Research Institute, Royal Childrens Hospital, Parkville, Australia;3. School of Mathematics and Statistics, The University of Melbourne, Parkville, Australia;4. National Centre for Immunisation Research and Surveillance, The Children''s Hospital at Westmead, Westmead, Australia;1. Division of Infectious Diseases and Hospital Epidemiology, University Children''s Hospital, Zurich, Switzerland;2. Children''s Research Centre, University Children''s Hospital, Zurich, Switzerland;3. Helsana Health Insurance Company, Duebendorf, Switzerland;1. Division of Bacteriology I, National Institute of Infectious Diseases, Tokyo, Japan;2. Division of Bacteriology, National Institute of Cholera and Enteric Diseases, Kolkata, India;1. Mathematics, School of Natural Sciences, Shiv Nadar University, India;2. Center for Infectious Disease Dynamics, Pennsylvania State University, USA;3. Fogarty International Center, National Institutes of Health, Bethesda, MD, USA |
| |
| Abstract: | For the development of a third generation of pertussis vaccine that could improve the control of the disease, it was proposed that the immune responses induced by the classic whole cell vaccine (wP) or after infection should be used as a reference point. We have recently identified a vaccine candidate based on outer membrane vesicles (OMVs) derived from the disease etiologic agent that have been shown to be safe and protective in mice model of infection. Here we characterized OMVs-mediated immunity and the safety of our new candidate. We also deepen the knowledge of the induced humoral response contribution in pertussis protection. Regarding the safety of the OMVs based vaccine (TdapOMVsBp,) the in vitro whole blood human assay here performed, showed that the low toxicity of OMVs-based vaccine previously detected in mice could be extended to human samples.Stimulation of splenocytes from immunized mice evidenced the presence of IFN-γ and IL-17-producing cells, indicated that OMVs induces both Th1 and Th17 response. Interestingly TdapOMVsBp-raised antibodies such as those induced by wP and commercial acellular vaccines (aP) which contribute to induce protection against Bordetella pertussis infection. As occurs with wP-induced antibodies, the TdapOMVsBp-induced serum antibodies efficiently opsonized B. pertussis. All the data here obtained shows that OMVs based vaccine is able to induce Th1/Th17 and Th2 mixed profile with robust humoral response involved in protection, positioning this candidate among the different possibilities to constitute the third generation of anti-pertussis vaccines. |
| |
| Keywords: | Acellular vaccine OMVs Protection Whooping cough |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
